- Home
- SWVL vs CRIS Comparison
SWVL vs CRIS Comparison
Compare SWVL & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWVL | CRIS |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United Arab Emirates | United States |
| Employees | 284 | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 14.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | SWVL | CRIS |
|---|---|---|
| Price | $1.80 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 21.4K | ★ 780.6K |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.57 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | $27.10 |
| Revenue Next Year | N/A | $67.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $1.31 | $0.49 |
| 52 Week High | $4.99 | $3.13 |
Technical Indicators
Market Signals| Indicator | SWVL | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 41.96 |
| Support Level | $1.33 | $0.49 |
| Resistance Level | $3.83 | $0.79 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 72.82 | 33.92 |
Price Performance
Historical ComparisonAbout SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.